retatrutids Retatrutide for weight loss: Study shows 30% body weight loss Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Consistent weekly dosing maintains steady drug levels needed for both weight loss and blood sugar control

Am J Physiol Gastrointest Liver Physiol (2007) 292(5):G136675.10.1152/ajpgi.00516.2006 22 OyaMKitaguchiTPaisRReimannFGribbleFTsuboiT

Use extra caution if you have cancer history, clotting disorders, cardiovascular disease, autoimmune conditions, or if you take anticoagulants, antiplatelet drugs, or immunomodulators

Benefits of Combining SGLT2 Inhibitors with GLP-1 Receptor Agonists on Cardiovascular Outcomes The summarized information indicates that the evidence from primary prevention studies is less robust than that derived from secondary prevention studies